Switch theme
Sign up to access all valuation multiples
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
1983
102
LTM Revenue $13.6M
Last FY EBITDA -$28.9M
$81.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ImmunoPrecise Antibodies has a last 12-month revenue (LTM) of $13.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, ImmunoPrecise Antibodies achieved revenue of $24.5M and an EBITDA of -$28.9M.
ImmunoPrecise Antibodies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ImmunoPrecise Antibodies valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | XXX | $24.5M | XXX | XXX | XXX |
| Gross Profit | $8.0M | XXX | $13.5M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$28.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -118% | XXX | XXX | XXX |
| EBIT | -$9.9M | XXX | -$12.2M | XXX | XXX | XXX |
| EBIT Margin | -73% | XXX | -50% | XXX | XXX | XXX |
| Net Profit | -$13.0M | XXX | -$30.2M | XXX | XXX | XXX |
| Net Margin | -95% | XXX | -123% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 1, 2025, ImmunoPrecise Antibodies's stock price is $2.
ImmunoPrecise Antibodies has current market cap of $79.6M, and EV of $81.6M.
See ImmunoPrecise Antibodies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $81.6M | $79.6M | XXX | XXX | XXX | XXX | $-0.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 1, 2025, ImmunoPrecise Antibodies has market cap of $79.6M and EV of $81.6M.
ImmunoPrecise Antibodies's trades at 3.3x EV/Revenue multiple, and -3.0x EV/EBITDA.
Equity research analysts estimate ImmunoPrecise Antibodies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ImmunoPrecise Antibodies has a P/E ratio of -4.5x.
See valuation multiples for ImmunoPrecise Antibodies and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $79.6M | XXX | $79.6M | XXX | XXX | XXX |
| EV (current) | $81.6M | XXX | $81.6M | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.0x | XXX | XXX | XXX |
| EV/EBIT | -6.1x | XXX | -6.4x | XXX | XXX | XXX |
| EV/Gross Profit | 7.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.5x | XXX | -2.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -12.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImmunoPrecise Antibodies's last 12 month revenue growth is 22%
ImmunoPrecise Antibodies's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
ImmunoPrecise Antibodies's rule of 40 is -88% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ImmunoPrecise Antibodies's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ImmunoPrecise Antibodies and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -110% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -88% | XXX | -88% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 105% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ImmunoPrecise Antibodies acquired XXX companies to date.
Last acquisition by ImmunoPrecise Antibodies was XXXXXXXX, XXXXX XXXXX XXXXXX . ImmunoPrecise Antibodies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ImmunoPrecise Antibodies founded? | ImmunoPrecise Antibodies was founded in 1983. |
| Where is ImmunoPrecise Antibodies headquartered? | ImmunoPrecise Antibodies is headquartered in United States of America. |
| How many employees does ImmunoPrecise Antibodies have? | As of today, ImmunoPrecise Antibodies has 102 employees. |
| Who is the CEO of ImmunoPrecise Antibodies? | ImmunoPrecise Antibodies's CEO is Dr. Jennifer L. Bath. |
| Is ImmunoPrecise Antibodies publicy listed? | Yes, ImmunoPrecise Antibodies is a public company listed on NAS. |
| What is the stock symbol of ImmunoPrecise Antibodies? | ImmunoPrecise Antibodies trades under IPA ticker. |
| When did ImmunoPrecise Antibodies go public? | ImmunoPrecise Antibodies went public in 2010. |
| Who are competitors of ImmunoPrecise Antibodies? | Similar companies to ImmunoPrecise Antibodies include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of ImmunoPrecise Antibodies? | ImmunoPrecise Antibodies's current market cap is $79.6M |
| What is the current revenue of ImmunoPrecise Antibodies? | ImmunoPrecise Antibodies's last 12 months revenue is $13.6M. |
| What is the current revenue growth of ImmunoPrecise Antibodies? | ImmunoPrecise Antibodies revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of ImmunoPrecise Antibodies? | Current revenue multiple of ImmunoPrecise Antibodies is 4.4x. |
| Is ImmunoPrecise Antibodies profitable? | Yes, ImmunoPrecise Antibodies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
